These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24037872)

  • 1. Imaging EGFR and HER2 by PET and SPECT: a review.
    Corcoran EB; Hanson RN
    Med Res Rev; 2014 May; 34(3):596-643. PubMed ID: 24037872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
    Schaefer G; Shao L; Totpal K; Akita RW
    Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Wang SE; Narasanna A; Perez-Torres M; Xiang B; Wu FY; Yang S; Carpenter G; Gazdar AF; Muthuswamy SK; Arteaga CL
    Cancer Cell; 2006 Jul; 10(1):25-38. PubMed ID: 16843263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Doebele RC; Oton AB; Peled N; Camidge DR; Bunn PA
    Lung Cancer; 2010 Jul; 69(1):1-12. PubMed ID: 20092908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy.
    Shang J; Shui Y; Sheng L; Wang K; Hu Q; Wei Q
    Oncol Rep; 2008 Feb; 19(2):435-40. PubMed ID: 18202792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography.
    Gelovani JG
    Cancer Metastasis Rev; 2008 Dec; 27(4):645-53. PubMed ID: 18626573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
    Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
    Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
    Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
    J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional histologic validation of high-resolution SPECT of antibody distributions within xenografts.
    Branderhorst W; Blezer EL; Houtkamp M; Ramakers RM; van den Brakel JH; Witteveen H; van der Have F; Gratama van Andel HA; Vastenhouw B; Wu C; Walsum MS; van Dongen GA; Viergever MA; Bleeker WK; Beekman FJ
    J Nucl Med; 2014 May; 55(5):830-7. PubMed ID: 24686779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
    Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular tracers for the PET and SPECT imaging of disease.
    Pimlott SL; Sutherland A
    Chem Soc Rev; 2011 Jan; 40(1):149-62. PubMed ID: 20818455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.